FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average I	hurden								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

hours per response: 0.5

1. Name and Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ]								(Chec	k all appli Directo	cable)	g Pers	son(s) to Iss 10% Ov Other (s	wner	
(Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600						3. Date of Earliest Transaction (Month/Day/Year) 09/16/2019								X	below)		ating	below) Officer		
(Street) REDWO CITY (City)	C.		94065 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	Form f	al or Joint/Group Filing (Check Applicable form filed by One Reporting Person form filed by More than One Reporting ferson				
		Tab	le I - No	n-Deriv	ative	Sec	curiti	ies Ac	quired,	Dis	posed c	of, or Be	enefic	ially	Owned	ł				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Execution Date		on Date,	Code (Insti		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			and 5) Securiti Benefic		es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Pric	е	Transac (Instr. 3	tion(s)			(111501.4)	
Common Stock, \$0.0001 par value 09/16/2					/2019	2019		M		2,500 A		\$2.	5005	5 21,810			D			
Common Stock, \$0.0001 par value 09/16/2				/2019	2019		S <sup>(1)</sup>		2,500	D	\$2	0.03	19	9,310		D				
		Т	able II -								osed of converti				Owned		,	•		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,		ransaction Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Own Forn Direc or In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisal		Expiration Date	Title	Amou or Numb of Share	oer						
Stock Option (Right to	\$2.5005	09/16/2019			М			2,500	(2)		06/30/2024	Common Stock	2,50	00	\$0.00	42,488	3	D		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- 2. All of the shares underlying this option are vested and exercisable as of the date hereof.

## Remarks:

Buy)

/s/ Jean Frederic Viret, as Attorney in Fact for Vincent R. 09/18/2019 <u>Anicetti</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.